Q-omics provides the consensus-scored COX6C profile across patient tissues and cancer cell-line models. COX6C expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, COX6C is differentially expressed in 13, with the highest sampling consensus in BRCA. Additionally, COX6C protein abundance shows 22,450 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, BRCA, and GBM as cancer lineages where COX6C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COX6C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COX6C survival associations across molecular data types. COX6C RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COX6C RNA expression–survival associations across cancer types. High COX6C expression shows unfavorable associations in UVM, ESCA, KIRC, UCS and COAD, but favorable associations in BRCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for COX6C RNA expression.
This table summarizes COX6C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in BRCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for COX6C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COX6C shows higher tumor expression in BRCA, KICH, LIHC, LUSC, LUAD and HNSC. The BRCA box plot shows higher COX6C RNA expression in tumor versus normal tissue (log2 FC = +2.044, t-test p < 0.001).
This table shows molecular features associated with COX6C in patient tissues and cancer cell lines. In patient samples, COX6C shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, COX6C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BONE.
